Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Conditions
Interventions
Canakinumab
Placebo
+1 more
Locations
1131
United States
Novartis Investigative Site
Athens, Alabama, United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Fairhope, Alabama, United States
Novartis Investigative Site
Huntsville, Alabama, United States
Start Date
April 11, 2011
Primary Completion Date
March 28, 2017
Completion Date
April 14, 2019
Last Updated
January 22, 2020
NCT01399385
NCT00353782
NCT01143454
NCT07241390
NCT05316311
NCT02932176
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions